[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584035":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":23,"interventions":35,"overallOfficials":16,"centralContacts":45,"locations":51,"responsibleParty":68,"collaborators":16,"id":70,"slug":16,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":16,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":16,"enrollmentInfo":79,"targetDuration":16,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":16,"overallStatus":54,"whyStopped":16,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Maximum concentration of drug in plasma (Cmax)","Cmax of AD-228B","pre-dose (0hour) to 72hours",{"measure":14,"description":15,"timeFrame":12},"Area under the plasma concentration-time curve during dosing interval (AUCt)","AUCt of AD-228B",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE",[24,31],{"label":25,"type":26,"description":27,"interventionNames":28},"Sequence A (RT)","EXPERIMENTAL","Period 1: Reference Drug (AD-2284), Period 2: Test Drug (AD-228B)",[29,30],"Drug: AD-228B","Drug: AD-2284",{"label":32,"type":26,"description":33,"interventionNames":34},"Sequence B (TR)","Period 1: Test Drug (AD-228B), Period 2: Reference Drug (AD-2284)",[29,30],[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":16},"DRUG","AD-228B","AD-228B, 1Tab., Per Oral",[25,32],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"AD-2284","AD-2284, 1Tab., Per Oral",[25,32],[46],{"name":47,"role":48,"phone":49,"phoneExt":16,"email":50},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",[52],{"facility":53,"status":54,"city":55,"state":16,"zip":16,"country":56,"countryCode":16,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"H Plus Yangji Hospital","RECRUITING","Seoul","South Korea",{"type":58,"coordinates":59},"Point",[60,61],126.9784,37.566,{"lat":61,"lon":60},[64],{"name":65,"role":48,"phone":66,"phoneExt":16,"email":67},"SeungHyun Kang","+82-70-4665-9490","juspa@newyjh.com",{"type":69,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100584035",false,"NCT06884098","A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":80,"type":81},60,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.",[87],"Primary Hypercholesterolaemia","2025-03-18",{"date":90,"type":91},"2025-03-20","ACTUAL",{"date":93,"type":91},"2025-03-10",{"date":95,"type":81},"2025-04",{"name":5,"class":6},1]